(Q35115898)

6 August 2017

title

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials (English)

1 reference

relapsing-remitting multiple sclerosis

6 August 2017

main subject

phase III clinical trial

0 references

multiple sclerosis

0 references

1 reference

Krzysztof Selmaj

6

0 references

Michael Hutchinson

object named as

Michael Hutchinson

8

0 references

Ralf Gold

14

object named as

Ralf Gold

1 reference

6 August 2017

3

Amit Bar-Or

1 reference

6 August 2017

2

David Miller

1 reference

6 August 2017

Vissia Viglietta

1

1 reference

6 August 2017

J Theodore Phillips

4

1 reference

6 August 2017

Douglas L Arnold

5

1 reference

6 August 2017

Mariko Kita

7

1 reference

6 August 2017

Minhua Yang

9

1 reference

6 August 2017

Ray Zhang

10

1 reference

6 August 2017

Katherine T Dawson

11

1 reference

6 August 2017

Sarah I Sheikh

12

1 reference

6 August 2017

Robert J Fox

13

1 reference

6 August 2017

language of work or name

1 reference

4 December 2014

1 reference

Annals of clinical and translational neurology

6 August 2017

published in

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

103-118

1 reference

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4338952

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4338952

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4338952

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4338952

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4338952

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study

9 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FACN3.148

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FACN3.148

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25750916

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/ACN3.148

1 reference

6 August 2017

1 reference

6 August 2017

1 reference